Compare DexCom, Inc. (DXCM) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? DexCom, Inc. trades at $77.27 (market cap $28.06B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $58.79. The key difference: Vanguard Emerging Markets Stock Index Fund ETF is trading nearer its 52-week high, DexCom, Inc. nearer its low. Which is the better fit depends on your goals.
| DXCM | VWO | |
|---|---|---|
Market Cap | $28.06B | — |
Sector | Health | — |
52-Week High | $89.53 | $61.24 |
52-Week Low | $54.84 | $49.54 |
Enterprise Value | $27.03B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
VWO trades at $58.73, down 0.59% today, with a neutral technical signal and bullish moving averages. The ETF offers broad emerging markets exposure with a low 0.06% expense ratio and a 2.4% dividend yield, though key valuation metrics are unavailable. Recent news highlights strong capital inflows into emerging markets and competitive positioning against higher-fee peers like EEM.
Outlook is supported by diversification benefits and cost efficiency, but risks include China's economic volatility and geopolitical tensions. Analyst sentiment is mixed, focusing on expense advantages versus concentrated emerging market risks. The fund's performance hinges on global economic trends and regional stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →
